Sub-therapeutic doses may fail to provide meaningful clinical benefit for diabetes or weight management and should only be considered under close medical supervision
Ideal candidates for Ozempic are adults with type 2 diabetes who are struggling to lower their blood sugar or reach their A1C goal
May be a marker of underlying disease (e.g., liver disease, malignancy, MDS/CML)
Nevertheless, the integration of two-year outcomes, rigorous propensity matching, millions of clinical notes analyzed through validated AI models, and one of the largest GLP-1RA-treated cohorts studied to date provides a robust characterization of real-world treatment heterogeneity
In South Carolina , state law (S.C
The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis